First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections
Angela K. Talley, Archie Thurston, Grayson Moore, Vipul K. Gupta, Myriah M Satterfield, Erika Manyak, S. Stokes, Aaron Dane, David Melnick
Abstract
was comparable between days 7 and 14. The results of this first-in-human study suggest that predicted therapeutic exposures of SPR719 can be attained with a once-daily oral administration of SPR720. (This study has been registered at ClinicalTrials.gov under registration no. NCT03796910.).
Topics & Concepts
TolerabilityPharmacokineticsMedicineAdverse effectGastroenterologyPharmacologyPlaceboInternal medicineDosingDNA gyraseVomitingBiologyPathologyEscherichia coliBiochemistryAlternative medicineGeneMycobacterium research and diagnosisTuberculosis Research and EpidemiologyInfectious Diseases and Mycology